The broad market finished Friday higher, but the cleaner message was not simply “buy technology.” A healthcare diagnostics company, a premium cruise operator and a diversified shipowner are each showing credible relative strength for different reasons.
This is a watchlist, not a prediction. The strongest candidate depends on whether its operating evidence continues—not merely whether its chart stays green for another day.
Market snapshot
Data point: Friday, July 31, 2026, at the 4:00 p.m. ET U.S. close (9:00 p.m. BST).
- The Dow Jones Industrial Average gained 0.53%.
- The S&P 500 gained 0.70%.
- The Nasdaq Composite gained 1.00%.
- The U.S. 10-year Treasury yield traded as high as 4.747%, keeping pressure on richly valued and highly leveraged companies.
- Oil rose more than $1 as traffic through the Strait of Hormuz remained thin.
The indexes recovered, but rising yields and geopolitical risk mean momentum still needs company-specific support. The three selections below were also identified in a weekend relative-strength screen published on August 2.
1. Guardant Health: the strongest catalyst, but also the most extended
Guardant Health reached a five-year high of $176.58 on Friday after reporting second-quarter revenue of $335 million, up 44% year over year, and raising its 2026 revenue outlook to $1.34 billion–$1.36 billion.
The operating story is broader than one earnings beat. In the first quarter, oncology-test volume rose 47%, Shield screening volume increased to roughly 44,000 tests from 9,000 a year earlier, and total revenue grew 48%. Expanded insurance coverage for the Shield colorectal-cancer blood test could support further adoption.
Catalyst: continued Shield uptake, oncology-volume growth and another guidance increase.
Evidence to watch: revenue growth, screening volume, reimbursement coverage and gross-margin progress—not the share price alone.
Main risk: Guardant is still loss-making, and the post-earnings move has pushed the stock well above its recent moving averages. A good business update can still produce a poor short-term entry after a large gap.
Invalidation condition: the momentum case weakens if management cuts its new revenue range, Shield volume falls behind guidance, or gross-margin gains reverse while spending remains elevated.
2. Viking Holdings: bookings provide unusual visibility for travel
Viking is showing relative strength while parts of the wider travel market remain sensitive to fuel costs and geopolitical disruption.
Its first-quarter revenue rose 17.5% to $1.05 billion, while adjusted EBITDA increased 43.9%. More importantly for forward visibility, Viking had sold 92% of its 2026 core capacity by May 3. Advance bookings were 13% higher for 2026 and 31% higher for 2027 than the comparable prior-year levels.
That does not remove cyclicality, but it gives Viking more evidence behind its momentum than a travel stock rising only because of sentiment.
Catalyst: resilient premium-travel demand, higher revenue per passenger cruise day and delivery of additional ships into already strong bookings.
Evidence to watch: booking growth, advance-booking prices, occupancy, net yield and whether EBITDA continues growing faster than capacity.
Main risk: fuel inflation, itinerary disruption, maintenance costs or a consumer slowdown could reduce margins even when ships remain relatively full.
Invalidation condition: the thesis weakens if advance bookings or booking prices turn negative year over year, occupancy drops materially, or leverage rises while new capacity expands.
3. Navios Maritime Partners: freight strength with more cyclicality attached
Navios Maritime Partners has rallied roughly 50% in 2026 and was trading near a widely watched $80.69 technical decision point late last week.
The company reported first-quarter revenue of $357.0 million, net income of $106.3 million, operating cash flow of $126.6 million and EBITDA of $212.7 million. Its mixed fleet of dry-bulk ships, containerships and tankers gives it exposure to several freight markets rather than one vessel category.
Shipping disruption can support rates and vessel utilisation, but it also makes the setup unusually headline-sensitive. Friday’s thin Hormuz traffic supports the current freight-risk premium; a durable diplomatic reopening could remove part of it.
Catalyst: sustained freight rates, high fleet utilisation, contracted revenue and continued unit repurchases.
Evidence to watch: charter rates, contract coverage, operating cash flow and the returns earned on the company’s new-vessel programme.
Main risk: shipping is deeply cyclical. Navios is committing substantial capital to new vessels, while lower freight rates or faster fleet growth could weaken future returns.
Invalidation condition: repeated failure near $80.69 followed by a break below the late-July base around $73.50, especially alongside falling charter rates or weaker cash flow, would damage the momentum case.
Which setup is strongest?
| Stock | What supports momentum | What could break it | Current read |
|---|---|---|---|
| Guardant Health | Fresh earnings beat, higher outlook, rapid test growth | Losses, valuation and a highly extended chart | Strongest catalyst; highest chase risk |
| Viking Holdings | Forward bookings and improving operating leverage | Fuel, disruption and consumer sensitivity | Cleanest visibility |
| Navios Maritime Partners | Cash generation, contracted revenue and freight risk premium | Cyclicality, newbuild spending and rate normalisation | Strong but headline-sensitive |
Guardant has the freshest catalyst, Viking has the clearest forward demand evidence, and Navios has the most direct exposure to disrupted global trade. None should be treated as automatically attractive at any price.
What could sustain the momentum next week
- Guardant: analysts raising estimates without a rapid deterioration in price structure.
- Viking: continued resilience in travel stocks despite high oil prices and bond yields.
- Navios: freight rates and shipping-risk premiums remaining firm while Hormuz traffic stays constrained.
- The wider market: the S&P 500 holding its recovery as investors digest the July jobs report and another heavy earnings week.
Bottom line
The useful signal is not that three unrelated stocks went up. It is that each has a measurable operating reason for its relative strength: Guardant’s revised growth outlook, Viking’s booked demand and Navios’s cash generation amid constrained shipping routes.
The next step is confirmation. Watch whether the catalyst continues, define what would invalidate it, and avoid turning recent strength into a reason to ignore valuation or risk.
Disclaimer: This article is for educational and informational purposes only. It is not financial advice, a recommendation, or an offer to buy or sell securities. Market prices and conditions can change quickly, and all figures should be independently verified before making a decision.
Sources
- Reuters — Stocks boosted by technology earnings as bond yields hit multi-year highs, July 31, 2026
- Reuters — Two VLCCs exit the Strait of Hormuz while traffic remains thin, July 31, 2026
- Reuters — U.S. market faces jobs report and a heavy earnings week, July 31, 2026
- Investor’s Business Daily — Five stocks showing relative strength, August 2, 2026
- Investor’s Business Daily — Guardant Health raises its 2026 outlook, August 1, 2026
- Guardant Health — First-quarter 2026 results and updated guidance, May 7, 2026
- Viking — First-quarter 2026 results and booking update, May 14, 2026
- Navios Maritime Partners — First-quarter 2026 results, May 21, 2026
- Investor’s Business Daily — Navios Maritime approaches a technical decision point, July 29, 2026